EpCAM+ ovarian cancer cell lines established from patients with chemotherapy-resistant disease (OSPC-ARK-1, OSPC-ARK-2, OSPC-ARK-4, CC-ARK1, and CC-ARK-2) treated with 5 μg/mL of adecatumumab displayed increased cytotoxicity compared to control [92]. Here, EPCAM is linked to ovarian carcinoma.